{"id":1910,"date":"2023-11-10T14:57:04","date_gmt":"2023-11-10T14:57:04","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1910"},"modified":"2026-02-22T23:50:39","modified_gmt":"2026-02-22T23:50:39","slug":"head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/","title":{"rendered":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace)"},"content":{"rendered":"<p>BALANCE is the first study directly comparing pegunigalsidase alfa with agalsidase beta for the treatment of patients with Fabry Disease (FD). At enrollment, participants had received previous agalsidase beta treatment for 6 years on average and had worsening kidney function. The participants were then randomly assigned to receive pegunigalsidase alfa or continue agalsidase beta. Results show these enzyme replacement therapies were comparable in how they affected the rate at which kidney function declined following random assignment. Participants tolerated pegunigalsidase alfa well and had lower rates of adverse events, especially infusion-related reactions, compared with participants receiving agalsidase beta. Pegunigalsidase alfa offers a new treatment option for adults with FD who have worsening kidney function. (<a href=\"https:\/\/jmg.bmj.com\/content\/early\/2023\/11\/07\/jmg-2023-109445\">https:\/\/jmg.bmj.com\/content\/early\/2023\/11\/07\/jmg-2023-109445<\/a> )<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BALANCE is the first study directly comparing pegunigalsidase alfa with agalsidase beta for the treatment of patients with Fabry Disease (FD). At enrollment, participants had received previous agalsidase beta treatment for 6 years on average and had worsening kidney function. The participants were then randomly assigned to receive pegunigalsidase alfa or continue agalsidase beta. Results [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1910","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"BALANCE is the first study directly comparing pegunigalsidase alfa with agalsidase beta for the treatment of patients with Fabry Disease (FD). At enrollment, participants had received previous agalsidase beta treatment for 6 years on average and had worsening kidney function. The participants were then randomly assigned to receive pegunigalsidase alfa or continue agalsidase beta. Results [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-10T14:57:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-22T23:50:39+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace)\",\"datePublished\":\"2023-11-10T14:57:04+00:00\",\"dateModified\":\"2026-02-22T23:50:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/\"},\"wordCount\":155,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/\",\"name\":\"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2023-11-10T14:57:04+00:00\",\"dateModified\":\"2026-02-22T23:50:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2023\\\/11\\\/10\\\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/","og_locale":"en_US","og_type":"article","og_title":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace) - JMG Contact blog","og_description":"BALANCE is the first study directly comparing pegunigalsidase alfa with agalsidase beta for the treatment of patients with Fabry Disease (FD). At enrollment, participants had received previous agalsidase beta treatment for 6 years on average and had worsening kidney function. The participants were then randomly assigned to receive pegunigalsidase alfa or continue agalsidase beta. Results [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/","og_site_name":"JMG Contact blog","article_published_time":"2023-11-10T14:57:04+00:00","article_modified_time":"2026-02-22T23:50:39+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace)","datePublished":"2023-11-10T14:57:04+00:00","dateModified":"2026-02-22T23:50:39+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/"},"wordCount":155,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/","url":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/","name":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2023-11-10T14:57:04+00:00","dateModified":"2026-02-22T23:50:39+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2023\/11\/10\/head-to-head-trial-of-pegunigalsidase-alfa-versus-agalsidase-beta-in-patients-with-fabry-disease-and-deteriorating-renal-function-results-from-the-2-year-randomized-phase-3-balance-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomized phase 3 BALANCE study (Contributed by Drs David G Warnock and Eric L Wallace)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1910"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1910\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}